Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine

Fochesato, Michel; Dendouga, Najoua; Boxus, Mathieu

doi:10.1080/21645515.2016.1154247

Cited by 21 publications

(25 citation statements)

References 20 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initial studies in mice confirm that the magnitude of the downstream adaptive humoral and cell-mediated immune response is higher when malaria and herpes-zoster antigens are co-injected with AS01 than when these antigens are administered alone [36][37][38]. In these experiments, AS01 performed better than other adjuvants.…”

Section: The Mode Of Action Of As01mentioning

confidence: 66%

See 1 more Smart Citation

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

Didierlaurent

Laupèze

Pasquale

et al. 2016

Expert Review of Vaccines

365

286

View full text Add to dashboard Cite

Introduction: Adjuvants are used to improve vaccine immunogenicity and efficacy by enhancing antigen presentation to antigen-specific immune cells with the aim to confer long-term protection against targeted pathogens. Adjuvants have been used in vaccines for more than 90 years. Combinations of immunostimulatory molecules, such as in the Adjuvant System AS01, have opened the way to the development of new or improved vaccines. Areas covered: AS01 is a liposome-based vaccine adjuvant system containing two immunostimulants: 3-O-desacyl-4ʹ-monophosphoryl lipid A (MPL) and the saponin QS-21. Here we describe studies investigating the mode of action of AS01, and consider the role of AS01 in enhancing specific immune responses to the antigen for selected candidate vaccines targeting malaria and herpes zoster. The effects of AS01 are rapid and transient, being localized to the injected muscle and draining lymph node. AS01 is efficient at promoting CD4 + T cell-mediated immune responses and is an appropriate candidate adjuvant for inclusion in vaccines targeting viruses or intracellular pathogens. Expert commentary: AS01 activity to enhance adaptive responses depends on synergistic activities of QS-21 and MPL. AS01 adjuvantation shows good prospects for use in new vaccines targeted to populations with challenging immune statuses and against diseases caused by complex pathogens. ARTICLE HISTORY

show abstract

Section: The Mode Of Action Of As01mentioning

confidence: 66%

“…In another study, AS01 induced better T-cell responses than other Adjuvant Systems i.e. AS04 (containing MPL and aluminum) or AS03 (vitamin E and squalene in an oilin-water emulsion) [38]. AS01 was therefore selected as adjuvant for the candidate herpes-zoster vaccine.…”

Section: Hz/su Herpes-zoster Vaccine Candidatementioning

confidence: 99%

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

Didierlaurent

Laupèze

Pasquale

et al. 2016

Expert Review of Vaccines

365

286

View full text Add to dashboard Cite

show abstract

“…an enhanced CMI response) [50]. Other Adjuvant Systems were therefore evaluated [51]. Among these, AS01 was a promising candidate, given the clinical experience with another AS01-adjuvanted vaccine, the RTS,S malaria vaccine, that consistently showed that AS01 can enhance T-cell responses in addition to antibodies with an acceptable safety profile in the populations studied [52,53].…”

Section: Adjuvant Selectionmentioning

confidence: 99%

Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention

Lecrenier

Beukelaers

Colindres

et al. 2018

Expert Review of Vaccines

View full text Add to dashboard Cite

GSK has developed a two-dose adjuvanted recombinant zoster vaccine (Shingrix, RZV) to protect people aged ≥50 years (50+) against herpes zoster (HZ) and its complications. RZV showed >90% efficacy against HZ, sustained over 4 years of follow-up, in all studied age groups. Areas covered: This article reviews the scientific rationale underlying the design of RZV; the clinical evidence demonstrating immunogenicity, safety, and efficacy in persons 50+; and the public health implications and cost-effectiveness. Expert commentary: A decline in varicella zoster virus (VZV) immunity is associated with increased risk of HZ in adults 50+ and immunocompromised individuals. RZV was designed to restore levels of anti-VZV cellular and humoral immunity to prevent VZV reactivation. RZV includes the recombinant gE glycoprotein antigen, and Adjuvant System AS01 which promotes cellular and antibody responses. In two Phase III studies in subjects aged 50+ and 70+ years, RZV efficacy against HZ compared to placebo was >90% and ≥89% against post-herpetic neuralgia (PHN). RZV is expected to dramatically impact HZ morbidity including its complications, and associated health-care costs. In the US population aged 50+ years, vaccination with RZV can be cost-effective compared to no vaccination and cost-saving compared to the currently available live-attenuated HZ vaccine (Zostavax, Merck).

show abstract

“…5,6 Therefore, CD4 + T cells expressing IL-2 and IFN-γ were selected as immune markers to evaluate cell-mediated immune responses to VZV vaccines. 4,[7][8][9] VZV gE is an attractive candidate for the development of VZV subunit vaccines because the VZV gE antigen, also known as CD4 + T-cell antigen, is capable of inducing both humoral and cell-mediated immune responses. [10][11][12][13] Vaccines currently used to prevent VZV include live attenuated vaccine (LAV) developed by Takahashi and colleagues in 1974 14 and several other varicella vaccines licensed in several countries.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of glycoprotein E subunit and live attenuated varicella‐zoster virus vaccines formulated with a single‐strand RNA‐based adjuvant

Lee

Park

et al. 2020

Immunity Inflam & Disease

View full text Add to dashboard Cite

Introduction: Varicella-zoster virus (VZV), a human alphaherpesvirus 3, elicits both chickenpox and shingles and/or postherpetic neuralgia. A live attenuated vaccine (LAV) and glycoprotein E (gE) subunit vaccine were developed to prevent VZV-induced diseases. We recently reported that single-strand RNA (ssRNA) based on the intergenic region of the internal ribosome entry site of cricket paralysis virus (CrPV) is an effective adjuvant for protein-based and virus-like particle-based vaccines. Here, Chinese hamster ovary expression system and an LAV from Oka/SK strains. Methods: We appraised the adjuvant effect of the same CrPV ssRNA encoding the gE gene formulated in the two vaccines using VZV-primed C57BL/6 mice and guinea pigs. Humoral immunity and cell-mediated immunity were assessed by enzyme-linked immunosorbent assay (ELISA) and ELISPOT in gE subunit vaccine and by ELISA and fluorescent antibody to membrane antigen in LAV. Results: The gE subunit vaccine-induced gE-specific antibodies and CD4 + T-cell responses (indicated by interferon-γ [IFN-γ] and interleukin-2 secretion) in the ssRNA-based adjuvant containing the VZV gE gene. Therefore, an ssRNA adjuvant combined with gE antigen can trigger the innate immune response and induce an adaptive immune response to ultimately activate humoral and cell-mediated responses. VZV LAV could also induce VZV-specific antibodies and IFN-γ stimulated by LAV, whereas the effect of ssRNA as a ---This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. contributed equally to this study.vaccine adjuvant could not be confirmed. However, the ssRNA adjuvant increased VZV-specific neutralizing antibody response. Conclusions: Taken together, these results highlight that the gE subunit vaccine and LAV developed in this study can be functional VZV vaccines, and ssRNAs appear to function better as adjuvants in a subunit vaccine than in an LAV. K E Y W O R D S chickenpox, gE subunit vaccine, live attenuated vaccine, RNA adjuvant, shingles, varicella-zoster virus

show abstract

Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine

Cited by 21 publications

References 20 publications

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention

Evaluation of glycoprotein E subunit and live attenuated varicella‐zoster virus vaccines formulated with a single‐strand RNA‐based adjuvant

Contact Info

Product

Resources

About